Last reviewed · How we verify
NicoDerm CQ Patch
NicoDerm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.
NicoDerm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation. Used for Smoking cessation aid in patients motivated to quit smoking.
At a glance
| Generic name | NicoDerm CQ Patch |
|---|---|
| Also known as | Nicotine patch, NRT |
| Sponsor | Chrono Therapeutics, Inc. |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
The patch provides a steady, controlled release of nicotine through the skin into the bloodstream, bypassing the need to smoke. This maintains nicotine levels to suppress cravings and withdrawal symptoms (irritability, anxiety, difficulty concentrating) while the user gradually reduces dependence. The transdermal route avoids the harmful combustion products of cigarettes while allowing behavioral modification.
Approved indications
- Smoking cessation as an aid to quit smoking
Common side effects
- Skin irritation at patch site
- Headache
- Nausea
- Dizziness
- Sleep disturbances
- Vivid dreams
Key clinical trials
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Rural Smoking Cessation (NA)
- My Path to Quit Tobacco (PHASE4)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension (PHASE2)
- Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders (PHASE3)
- Depressed Mood Improvement Through Nicotine Dosing 3 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NicoDerm CQ Patch CI brief — competitive landscape report
- NicoDerm CQ Patch updates RSS · CI watch RSS
- Chrono Therapeutics, Inc. portfolio CI